Addiction

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for 2026Detroit, MI, Dec. 27, 2025…

2 weeks ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope Treatment Center are encouraging individuals…

3 weeks ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

3 weeks ago

NetraMark Delivers Transformational Quarter Of Execution

Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award…

4 weeks ago

NetraMark Delivers Transformational Quarter Of Execution

Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award…

4 weeks ago

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple…

4 weeks ago

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple…

4 weeks ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

4 weeks ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

4 weeks ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

4 weeks ago